

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q86405

Hisao NAKAI, et al.

Appln. No.: National Stage Entry of PCT/JP03/10401

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: February 18, 2005

Examiner: Unknown

For: NITROGEN-CONTAINING COMPOUNDS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: National Stage Entry of PCT/JP03/10401
Attorney Docket No.: Q86405

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of an English Language International Search Report from the International Searching Authority in the International Application, including at least that portion of the International Search Report indicating the degree of relevance found by the International Searching Authority.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,



Mark Boland
Registration No. 32,197

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 18, 2005

Substitute for Form 1449 A & B/PTO <u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u> <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	National Stage Entry of PCT/JP03/10401
				Confirmation Number	Unknown
				Filing Date	February 18, 2005
				First Named Inventor	Hisao NAKAI
				Art Unit	Unknown
				Examiner Name	Unknown
				Attorney Docket Number	Q86405
Sheet	1	of	1		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² <i>(if known)</i>		
		US			
		US			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ <i>(if known)</i>			
		WO	02/14271	A	02-21-2002	Welfide Corp.	
		JP	9-509921	A	10-07-1997	Ferring B.V.	
		WO	02853170	A	07-11-2002	Institut Fuer Medizintechnologie Magdeburg G.m.b.H.	
		WO	02/53169	A	07-11-2002	Keyneurotek A.-G. I.G.	
		JP	2002-516318	A	06-04-2002	Probiodrug Gesellschaft fur Arzneimittelforschung	
		JP	2-262557	A	10-25-1990	Zeria Pharmaceutical Co., Ltd.	
		JP	2-179	A	01-05-1990	Yamanouchi Pharmaceutical Co., Ltd.	
		JP	2-129168	A	05-17-1990	Dr. Lo. Zambelletti S.p.A.	
		WO	90/07502	A	07-12-1990	Zambelletti, Dr. L., S.p.A.	
		JP	1-308250	A	12-12-1989	Glaxo Group Ltd.	
		JP	63-146860	A	06-18-1988	Dr. Lo. Zambelletti S.p.A.	
		WO	03/57666	A	07-17-2003	Guilford Pharmaceuticals	
		WO	03/57144	A	07-17-2003	Guilford Pharmaceuticals	
		WO	03/24942	A	03-27-03	Mitsubishi Pharma Corp.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		ASHWORTH, Doreen M. et al, "2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV, Bioorganic & Medicinal Chemistry Letters (1996) Vol. 6 No. 10, pp. 1163-1166	
		KANAI, Karoly et al, "Prolyl endopeptidase inhibitors, 2. N-acyl derivatives of L-thioproline-pyrrolidine, Bioorganic & Medicinal Chemistry Letters (1997) Vol. 7 No. 13, pp. 1701-1704	
		YOSHIMOTO, Tadashi et al, "Specific inhibition of dipeptidyl aminopeptidase IV by a new synthetic inhibitor, L-thiopropylthiazolidine, Agricultural and Biological Chemistry (1991) Vol. 55 No. 4, pp. 1135-1136	
		SCOPES, David I.C. et al, "New. Kappa.-receptor agonists based upon a 2-[(alkylamino) methyl] piperidine nucleus," Journal of Medicinal Chemistry (1992), Vol. 35 No. 3, pp. 490-501	
		VECCHIETTI, Vittorio et al, " (2s)-1-(Arylacetyl)-2- (aminomethyl)piperidine derivatives: novel, highly selective .kappa. opioid analgesics" Journal of Medicinal Chemistry (1991) Vol. 34, No. 1, pp. 397-403	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.